דילוג לתוכן הראשי
xMedica

NCT05922878ClinicalTrials.gov

Study of ALTO-300 in MDD

A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder

מגייסמקבל משתתפים כעת, לפי רשומת המרשם.
יצירת קשר עם המחקר

בקצרה

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

שלב 2דרושים 325 משתתפים75 אתריםמדינה אחת

קטגוריות

רשום במרשם אחד

מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.

מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.

מתעניינים במחקר הזה?

התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2023-06-28; recorded start 2023-06-08
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Alto Neuroscience)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 45 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 325 participants (target), run at 75 sites.

How this score is built
  • Enrolment24/40

    321 participants (target)

  • Site count19/25

    45 sites

  • Country count0/15

    Single country

  • Planned duration8/10

    Planned over about 42 months

  • Sponsor scale2/10

    Alto Neuroscience has led 5 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

תקציר

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

מצבים רפואיים

  • Major Depressive Disorder

זכאות

זכאות
מיןהכול
גילאים18 Years – 70 Years
מתנדבים בריאיםלא

זכאות כפי שנכתבה במרשם

Inclusion Criteria: * Have a diagnosis of moderate to severe major depressive disorder (MDD) * At Visit 1, currently taking a stable dose of 1 or 2 antidepressants (e.g., SSRI, SNRI, bupropion, or gepirone) for at least 6 weeks with no dose modifications in the past 2 weeks by Visit 2 * Willing to comply with all study assessments and procedures * Must not be pregnant or breastfeeding at time of enrollment or throughout study Exclusion Criteria: * Evidence of unstable medical condition * Nightly use of sleep medication * Diagnosed bipolar disorder, psychotic disorder, or dementia * Current moderate or severe substance use disorder * Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients * Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device

זכאות במשפטים פשוטים

הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.

תכנון המחקר

תכנון המחקר
סוג המחקרהתערבותי
שלבשלב 2
הקצאהאקראי
מודל ההתערבותPARALLEL
מטרה ראשיתTREATMENT
הסתרהQUADRUPLE (4)
גיוסדרושים 325 משתתפים

נותן חסות ושותפים

  • Alto Neuroscience נותן חסות

זרועות והתערבויות

  • ALTO-300EXPERIMENTAL

    Participants will receive ALTO-300 25mg capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open-label (OL) treatment period will receive ALTO-300 capsule once daily in the evening from OL baseline until the end of OL period/early termination visit (Up to 8 weeks).

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive matching placebo capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period.

התערבויות

  • תרופה ALTO-300

    ALTO-300 capsule QD

  • תרופה Placebo

    Placebo capsule QD

מדדי תוצאה

  1. מדד תוצאה ראשוני

    To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS).

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    מסגרת זמן Change over time for up to week 6

  2. מדד תוצאה משני

    To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in all randomized participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS)

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    מסגרת זמן Change over time for up to week 6

  3. מדד תוצאה משני

    To assess efficacy of adjunctive ALTO-300 versus placebo for MDD as measured by the change over time up to week 6 in response (>50% improvement from baseline) rates based on the MADRS

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    מסגרת זמן Change over time for up to week 6

  4. מדד תוצאה משני

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of the incidence, severity, and relatedness of Adverse Events.

    Incidence, severity, and relatedness of Adverse Events

    מסגרת זמן Assessed from Day 1 to Week 14

  5. מדד תוצאה משני

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Heart Rate.

    Assessment of Heart Rate

    מסגרת זמן Assessed from Day 1 to Week 14

  6. מדד תוצאה משני

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Weight.

    Assessment of Weight Change

    מסגרת זמן Assessed from Day 1 to Week 14

  7. מדד תוצאה משני

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Blood Pressure.

    Assessment of Blood Pressure

    מסגרת זמן Assessed from Day 1 to Week 14

  8. מדד תוצאה משני

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of suicidality with the Concise Health Risk Tracking Self-Report,12 item scale (CHRT-SR12).

    The CHRT is a brief, self-report measure that systematically assesses both suicidal thinking and associated thoughts that may indicate the propensity for suicidal acts. The CHRT-SR12 is a 12 item scale. The patient assigns a score of 0-4 for each item of the scale, allowing for a total score of 0 to 48, with the higher score signifying more severe symptoms.

    מסגרת זמן Assessed from Day 1 to Week 15

תאריכים

תאריכים
תאריך התחלה8 ביוני 2023 (בפועל)
סיום ראשוני1 בדצמבר 2026 (משוער)
סיום1 בדצמבר 2026 (משוער)
פורסם לראשונה28 ביוני 2023 (בפועל)
עודכן לאחרונה26 באוקטובר 2026
התוצאות פורסמולא צוין ברשומת המרשם
המצב אומת לאחרונהאוקטובר 2026

בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.

מיקומים

30 אתרים מגייסים

United States

United States
מתקןעירמדינה או אזורמצב
Site 114AlbuquerqueNew Mexicoמגייס
Site 216AllentownPennsylvaniaהופסק
Site 316AustinTexasמגייס
Site 218BellflowerCaliforniaמגייס
Site 317BlackfootIdahoבוטל
Site 236BoiseIdahoמגייס
Site 119BoiseIdahoפעיל, ללא גיוס
Site 318CarlsbadCaliforniaפעיל, ללא גיוס
Site 310ChicagoIllinoisפעיל, ללא גיוס
Site 202CincinnatiOhioמגייס
Site 159ClermontFloridaהופסק
Site 207ClintonUtahפעיל, ללא גיוס
Site 203Colorado SpringsColoradoפעיל, ללא גיוס
Site 239ConroeTexasמגייס
Site 229Creve CouerMissouriבוטל
Site 102DallasTexasפעיל, ללא גיוס
Site 343DenverColoradoמגייס
Site 349EvergreenColoradoפעיל, ללא גיוס
Site 345EvergreenColoradoפעיל, ללא גיוס
Site 277FairfaxVirginiaמגייס
Site 238FayettevilleGeorgiaמגייס
Site 148Fort WorthTexasבוטל
Site 347Fort WorthTexasהופסק
Site 217GlendaleCaliforniaפעיל, ללא גיוס
Site 279HattiesburgMississippiבוטל
Site 199HickoryNorth Carolinaפעיל, ללא גיוס
Site 320HoustonTexasמגייס
Site 275HoustonTexasמגייס
Site 215JacksonMississippiפעיל, ללא גיוס
Site 335LafayetteCaliforniaמגייס
Site 335LafayetteCaliforniaמגייס
Site 344Las VegasNevadaמגייס
Site 209Los AngelesCaliforniaפעיל, ללא גיוס
Site 240MankatoMinnesotaמגייס
Site 201MarreroLouisianaהופסק
Site 219MatherCaliforniaמגייס
Site 350MediaPennsylvaniaבוטל
Site 225Miami GardensFloridaפעיל, ללא גיוס
Site 190Miami LakesFloridaפעיל, ללא גיוס
Site 265MinneapolisMinnesotaמגייס
Site 194Mission ViejoCaliforniaהופסק
Site 206Missouri CityTexasבוטל
Site 198MonroeLouisianaהופסק
Site 267MoorparkCaliforniaמגייס
Site 352MoosicPennsylvaniaפעיל, ללא גיוס
Site 283New YorkNew Yorkמגייס
Site 319New YorkNew Yorkפעיל, ללא גיוס
Site 214NorwalkConnecticutבוטל
Site 161OkeechobeeFloridaפעיל, ללא גיוס
Site 195Oklahoma CityOklahomaהופסק

25 אתרים נוספים מצוינים ברשומת המרשם.

מסמכי המחקר

לא צורפו מסמכים ברשומת מרשם זו.

שינויים לאורך זמן

  1. 26 באוקטובר 2026

    יעד הגיוס השתנה

    Enrollment target revised up from 321 to 325

    321325

  2. 26 באוקטובר 2026

    אתר נוסף

    30 sites added (75 total)

    4575